OBJECTIVE：To observe the efficacy and safety of weifuchun tablet combined with rabeprazole enteric-coated tablet in the treatment of chronic gastritis with reflux esophagitis. METHODS： 894 gastritis patients with reflux esophagitis were randomly divided into control group （407 cases） and observation group （487 cases）. Control group was given 10 mg Rabeprazole enteric-coated tablet， once a day； observation group was additionally given 1 440 mg Weifuchun tablet， orally， 3 times a day. The treatment course for both groups was 4-8 weeks. Clinical efficacy， microscopic examination grading，total symptom scores， self-rating anxiety scores （SAS）， self-rating depression scores （SDS）， quality of life scale score（QOLS）， Memorial University of Newfoundland Scale of Happiness score（MUNSH） of reflux esophagitis before and after treatment， and incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， the difference was statistically significant （P＜0.01）. Before treatment， there were no significant differences in the microscopic examination grading， symptom scores， SAS， SDS， QOLS and MUNSH scores between 2 groups （P＞0.05）； after treatment， the microscopic examination grading cases in 2 groups were significantly superior to before， observation group was superior to control group， total symptom scores， SAS and SDS scores were significantly lower than before， observation group was lower than control group， QOLS and MUNSH scores were significantly higher than before， observation group was higher than control group， the differences were statistically significant （P＜0.05 of P＜0.01）. And there was no significant difference in the incidence of adverse reactions between 2 groups （P＞0.05）. CONCLUSIONS： Weifuchun tablet combined with rabeprazole enteric-coated tablet has better efficacy than only rabeprazole in the treatment of chronic gastritis with reflux esophagitis， it can relieve clinical symptoms of patients， with better safety.